According to a recent report by Fact.MR, the global lung cancer diagnostics market is anticipated to register 7.3% CAGR throughout the forecast period 2017 to 2022.

Growth of the global lung cancer diagnostics market is mainly attributed to surging developments in the lung cancer-specific biomarkers. Diagnostic tools, such as these, will facilitate personalized treatment approach for lung malignancies. Numerous biomarkers are in the research pipeline.

Epigenomics AG has launched a new test which is based on blood by utilizing DNA methylation biomarkers, and their developments are in process. Initial results of these tests have guaranteed early diagnosis of lung cancer. These incidences are most likely to increase demand for diagnosis of lung cancer across the globe.

In this lung cancer diagnostics market study, the following years are considered to project the market footprint:

History Year: 2012-2016
Base Year: 2012
Estimated Year: 2022
Forecast Year: 2017 – 2022

After reading the lung cancer diagnostics market report, readers can:

Understand the drivers, restraints, opportunities and trends affecting the growth of the global lung cancer diagnostics market.
Analyze key regions holding significant share of the total lung cancer diagnostics market revenue.
Study the growth outlook of the global lung cancer diagnostics market scenario, including production, consumption, history and forecast.
Learn consumption pattern and impact of each end use on the lung cancer diagnostics market growth.
Investigate the recent R&D projects performed by each lung cancer diagnostics market player.

Request for the Sample of the Report: https://www.factmr.com/connectus/sample?flag=S&rep_id=49

The lung cancer diagnostics market report covers the following regions:

North America (U.S., Canada)
Latin America (Mexico, Argentina)
Europe (France, Spain)
APEJ (India, Malaysia)

On the basis of test type, the lung cancer diagnostics market report considers the following segments:

CA Test
HER2 Tests
ALK Tests
Angiogenesis Inhibitor
EGFR Mutation Tests
KRAS Mutation Tests

On the basis of end-user, the lung cancer diagnostics market report includes:

Hospital Associated Labs
Independent Diagnostic Laboratories
Cancer Research Institutes

Prominent lung cancer diagnostics market players covered in the report contain:

Danaher Corporation
Roche Holding AG
NanoString Technologies Inc
NeoGenomics Laboratories, Inc
Quest Diagnostics Incorporated
QIAGEN N.V
Thermo Fisher Scientific, Inc
Illumina, Inc
Abbott Laboratories
Myriad Genetics Inc

The behavior pattern of each player – new product launches, partnerships, and acquisitions – has been analyzed in the lung cancer diagnostics market report comprehensively. In addition, the research encompasses the strengths, weaknesses, opportunities and threats of each lung cancer diagnostics market vendor in an in-depth manner.

The lung cancer diagnostics market report answers important questions which include:

What does the status of the lung cancer diagnostics market look like after the forecast period?
Which region has the highest contribution to the global lung cancer diagnostics market and why?
Which players remain at the top of the global lung cancer diagnostics market?
What opportunities are available for the lung cancer diagnostics market players to expand their production footprint?
Which segment has the maximum impact on the global lung cancer diagnostics market?

Request for Report Methodology: https://www.factmr.com/connectus/sample?flag=RM&rep_id=49

Why Opt For Fact.MR?

Various analysis methods to deliver precise market information.
Digital technologies to facilitate clients with updated market solutions.
Multi-disciplinary approach to provide accurate insights of different industries.
Data collection from extensive primary and secondary research.
Round-the-clock availability to serve clients across the world.